Sign In
Buy VXRT
$0.519
-0.0111 (-2.09%)
At Close: Jun 23, 2026
Vaxart Answers Additional Frequently Asked Questions from Retail Investors
08:00am, Wednesday, 28'th May 2025
Company Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on June 1, 2025 SOUTH SAN FRANCISCO, Calif.
Vaxart Initiates Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial
08:00am, Tuesday, 27'th May 2025
- Study will assess relative efficacy, safety, and immunogenicity of Vaxart's oral pill COVID-19 vaccine candidate against an approved mRNA comparator at 12 months - SOUTH SAN FRANCISCO, Calif., May 2
Vaxart Announces Adjournment of Annual Meeting of Stockholders
04:45pm, Wednesday, 21'st May 2025
Meeting adjourned to June 2, 2025 at 8:30 a.m. Pacific Time Vaxart encourages all stockholders of record on March 26, 2025 who have not yet voted to do so by 11:59 p.m.
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05:00pm, Tuesday, 20'th May 2025
SOUTH SAN FRANCISCO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that the Compensation Committee of the Board of Directors
Company Urges Stockholders to Vote ‘FOR' Reverse Stock Split Proposal at Upcoming Annual Meeting to Avoid Nasdaq Delisting Leading Independent Proxy Advisory Firms, ISS and Glass Lewis, Support Prop
Vaxart Receives BARDA Approval to Initiate Dosing in 10,000-Participant Portion of Phase 2b COVID-19 Trial
08:00am, Thursday, 15'th May 2025
SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has received approval from the Biomedical Advanced Research and Development Authority
Challenge Study measured safety, efficacy against infection and symptomatic disease as well as viral shedding Machine learning analyses identified statistically significant correlates of protection an
Vaxart, Inc. (VXRT) Q1 2025 Earnings Call Transcript
08:43pm, Tuesday, 13'th May 2025
Vaxart, Inc. (NASDAQ:VXRT ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Ed Berg - SVP and General Counsel Steven Lo - CEO James Cummings - CMO Sean Tucker - Founder a
Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results
04:05pm, Tuesday, 13'th May 2025
Actively screening for the 10,000 participant portion of COVID-19 Phase 2b trial; Dosing expected to begin in second quarter of 2025 Completed enrollment of Phase 1 clinical trial evaluating Company's
Vaxart Appoints Jeroen Grasman as Chief Financial Officer
04:01pm, Tuesday, 13'th May 2025
- Mr. Grasman brings over two decades of biotech financial leadership experience - SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the appoint
Vaxart Addresses Frequently Asked Questions on Reverse Stock Split Proposal in Definitive Proxy Statement
08:00am, Monday, 12'th May 2025
Company Urges Stockholders to Vote FOR Reverse Stock Split Proposal at Upcoming Annual Meeting to Avoid Nasdaq Delisting SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nas
Vaxart CEO Issues Letter to Stockholders Highlighting Company Progress
08:00am, Monday, 05'th May 2025
Urges Stockholders to Vote FOR Reverse Stock Split Proposal at Upcoming Annual Meeting as Recommended by Leading Independent Proxy Advisory Firms SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSW
Vaxart to Host First Quarter 2025 Business Update and Financial Results Conference Call on May 13
08:00am, Friday, 02'nd May 2025
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif.
Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate
08:00am, Wednesday, 30'th Apr 2025
- Topline data expected in mid-2025 - SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it completed enrollment of its Phase 1 clinical t
Vaxart to Present at World Vaccine Congress Washington 2025 on April 23
08:00am, Wednesday, 16'th Apr 2025
SOUTH SAN FRANCISCO, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, and Dr. James F.
